AU3220593A - Soluble mhc molecules and their uses - Google Patents

Soluble mhc molecules and their uses

Info

Publication number
AU3220593A
AU3220593A AU32205/93A AU3220593A AU3220593A AU 3220593 A AU3220593 A AU 3220593A AU 32205/93 A AU32205/93 A AU 32205/93A AU 3220593 A AU3220593 A AU 3220593A AU 3220593 A AU3220593 A AU 3220593A
Authority
AU
Australia
Prior art keywords
mhc molecules
soluble mhc
soluble
molecules
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32205/93A
Inventor
Randall J Armstrong
H. E Selick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergen Inc
Original Assignee
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anergen Inc filed Critical Anergen Inc
Publication of AU3220593A publication Critical patent/AU3220593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
AU32205/93A 1991-11-19 1992-11-18 Soluble mhc molecules and their uses Abandoned AU3220593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79589791A 1991-11-19 1991-11-19
US795897 1991-11-19

Publications (1)

Publication Number Publication Date
AU3220593A true AU3220593A (en) 1993-06-15

Family

ID=25166732

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32205/93A Abandoned AU3220593A (en) 1991-11-19 1992-11-18 Soluble mhc molecules and their uses

Country Status (2)

Country Link
AU (1) AU3220593A (en)
WO (1) WO1993010220A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
PL320922A1 (en) * 1994-12-23 1997-11-10 Om Lab Sa Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6140113A (en) * 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
AU770938B2 (en) * 1996-03-28 2004-03-11 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
EP0889964A1 (en) * 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
ES2221065T3 (en) * 1996-08-16 2004-12-16 The President And Fellows Of Harvard College MHC CLASS II FUSION PROTEINS, SOLUBLES, MONOVALENTS OR POLIVALENTS, AND THEIR USES.
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999009064A1 (en) 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
FR2796953B1 (en) * 1999-07-29 2003-10-10 Centre Nat Rech Scient RECOMBINANT PROTEINS, AND MOLECULAR COMPLEXES DERIVED FROM SUCH PROTEINS, ANALOGS TO MOLECULES INVOLVED IN IMMUNE RESPONSES
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
DE102004022435A1 (en) * 2004-05-06 2005-12-08 Imusyn Gmbh & Co.Kg Process for the preparation of soluble MHC proteins
GB2422834B8 (en) 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
GB2424645B (en) 2005-04-01 2007-06-06 Proimmune Ltd Method of producing a set of MHC molecules
GB2440529B (en) 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US9139809B2 (en) 2009-01-08 2015-09-22 Albert Einstein College Of Medicine Of Yeshiva University Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US20230287394A1 (en) 2020-03-31 2023-09-14 Repertoire Immune Medicines, Inc. Barcodable exchangeable peptide-mhc multimer libraries
WO2022087154A1 (en) 2020-10-20 2022-04-28 Repertoire Immune Medicines, Inc. Mhc class ii peptide multimers and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide

Also Published As

Publication number Publication date
WO1993010220A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
AU3220593A (en) Soluble mhc molecules and their uses
AU2103097A (en) Cinnoline derivatives and use as medicine
AU7579991A (en) Pseudonucleosides and pseudonucleotides and their polymers
AU1959992A (en) 3-aryl-4-hydroxy-3-dihydrofuranone and 3-aryl-4-hydroxy- 3-dihydrothiophenone derivatives
AU7237394A (en) Morphinan derivative and medicinal use
AU7991491A (en) Highly reflective biogratings and method
AU5619894A (en) Dna-armed ribozymes and minizymes
AU663637B2 (en) Solutions and their preparation
AU8328691A (en) Isocarbostiryl compounds and antitumor use thereof
EP0634836A3 (en) Distributed amplifier and bidirectional amplifier
AU6662490A (en) Modified gangliosides and the functional derivatives thereof
AU4183993A (en) Easel
AU3397793A (en) Binder and its uses
AU5067193A (en) Pyranoquinolines and their use as pharmaceuticals
AU6899994A (en) Novel macrolides and the use thereof
AU2966392A (en) Transparent part and use thereof
AU7231494A (en) Human mhc class ii double transgene and uses
AU4100593A (en) Iminoalcohol-oxazolidine mixtures and their use
AU4238093A (en) Novel retinol derivatives and uses thereof
AU1911892A (en) Portable signs and like structures
AU7019794A (en) Oligomer conjugates and their use
AU7424491A (en) New ethylene-substituted phenylalkylethylenediamine- platinum (ii or iv) derivatives and phenylalkylethylenediamines
AU631448B2 (en) Application aid and the use thereof
AU647559B2 (en) Pyrimidinyl- and triazinyl-salicylamides and their use and preparation
AU1106392A (en) Composition and use